Consumers' price responsiveness is central to current reform proposals to address rapidly escalating health care costs, but the best available estimates of price elasticities of demand are now more than 25 years old. We seek to provide more current estimates of the demand for both mental and physical health treatment using a health care demand model that incorporates the relevant costs influencing consumption decisions, including out-of-pocket payments (costsharing) for ambulatory services, out-of-pocket prescription drug costs, and insurance premiums. Following Ellis (1986) and Ellis and McGuire (1986) , we use consumers' out-of-pocket payments to derive theoretically appropriate expected end-of-year prices. The demand model is estimated using the 1996-2003 Medical Expenditure Panel Survey (MEPS), a nationally representative survey of the U.S. civilian, non-institutionalized population. We address the potential endogeneity of expected end-of-year prices and health insurance coverage (or adverse selection) by estimating a correlated random effects specification (Chamberlain, 1980) . This allows us to relax the untenable assumption of standard random effect models that price and health insurance are uncorrelated with unobserved individual attributes. We find that the price responsiveness of ambulatory mental health visits has decreased substantially in the last 30 years and is now slightly less elastic than visits for physical health problems. However, the demand for both mental health and non-mental prescription drugs is substantially more price elastic. We discuss the implications of our results.
Introduction
Optimal second-best insurance requires balancing the gains from risk-spreading with the welfare losses due to moral hazard (Zeckhauser, 1970) . This balancing in health insurance coverage is analogous to Ramsey pricing (Besley 1988; Zeckhauser 1970; Baumol and Bradford 1970) . That is, the level of consumer cost-sharing (or the out of pocket price that consumers face) should be positively related to the price elasticity of demand-the higher the price elasticity, the higher the cost-sharing. Current proposals for health care reform, such as Health Savings Accounts, are predicated on the notion that shifting more costs directly to consumers will reduce unnecessary medical use and help restrain rapidly escalating health care costs (Fuchs and James, 2005) . Price elasticites are also central to continued debates over benefit mandates, such as requiring insurers to cover particular services such as mammograms or to provide equal coverage for mental health treatment (or mental health parity). Therefore, the question of how elastic the demand for health care is and whether it varies by type of treatment has far reaching implications for private insurers and public policy makers.
The best available evidence on price elasticities for health care comes from the RAND Health Insurance Experiment (HIE), a large-scale randomized experiment conducted from 1977 to 1982 (Manning et al., 1987) . The RAND HIE found price elasticities of around -.2 for all types of medical care, but considerable variation for different types of treatment. In particular, the demand for outpatient psychotherapy visits was found to be approximately three times more price elastic than for other medical visits (Keeler, Manning, and Wells, 1988) . This important finding, consistent with observational studies from the same period (Horgan, 1986; McGuire 1981) , has been used to justify higher cost-sharing for mental health treatment in the years since (Frank, Goldman, and McGuire, 1992) .
Many question how relevant the RAND HIE estimates still are today given the rapid advances in medical technology that occurred over the last 25 years and the growth of managed care. Economists (Glied 2003; Cutler 2002; Newhouse 1993) generally credit medical advances with being the major force driving health care expenditures from $255 billion in 1980, or 10.4% of GDP to an estimated $2.1 trillion in 2006, or 16.0% of GDP (Heffler et al. 2005) . The development of less-invasive surgical procedures that can be performed on an outpatient basis, new diagnostic and imaging procedures, and new treatments and therapies have all led millions more to seek treatment for their health conditions (Thorpe et al., 2004) . Especially important was the introduction of many new classes of prescription drugs, such as lipid-lowering statins and new types of anti-depressants like Prozac and Paxil. As a result, prescription drug spending grew at twice the rate of other types of medical care spending over the last decade (Heffler et al. 2005 ). Perhaps nowhere is the change in medical technology more evident than in the treatment of mental health problems. Traditional psychotherapy, the standard of treatment during the RAND HIE, has largely given way to prescription drug based treatment, practiced alone or in combination with newer talk therapies, such as cognitive behavioral therapy. As a result, the number of Americans in treatment nearly doubled from 16.5 million in 1987 (Zuvekas, 2001 ) to 30.5 million in 2001 (Zuvekas, 2005) .
Clearly, the demand for mental health treatment and many other types of medical treatment shifted outwards since the RAND HIE twenty-five to thirty years ago. But we might expect the same medical advances that led to demand shifts to also change the shape of the demand curves. The demand for medical care is usually thought of as a derived demand for health, and therefore dependent on the current state of medical technology. In other words, consumers are purchasing entirely different bundles of goods now than they did decades earlier.
Furthermore, changes in the institutional coverage for mental and physical health treatment and their associated prescription medications brought about by managed care and the expanding role of the public sector in health insurance markets could also influence relative demand levels and price responsiveness.
We seek to provide current estimates of the demand for both physical and mental health treatment, and in particular the price elasticity of demand for different types of treatment including prescription drugs.
1 Therefore, we derive a health care demand model that incorporates the relevant costs influencing consumption decisions, including out-of-pocket payments (costsharing) for ambulatory services, out-of-pocket prescription drug costs, and insurance premiums.
Following Ellis (1986) and Ellis and McGuire (1986) , we use consumers' out-of-pocket payments to derive theoretically appropriate expected end-of-year prices for different types of We address the potential endogeneity of expected end-of-year prices and health insurance coverage (or adverse selection), which typically confound observational studies, by exploiting the longitudinal dimension of the MEPS to estimate a correlated random effects specification (Chamberlain, 1980) . This allows us to relax the untenable assumption of standard random effect models that price and health insurance are uncorrelated with the unobserved individual attributes, such as unobserved physical and mental health status and preferences for treatment. The specification can also be seen as a reasonable way to account for time invariant measurement error processes.
m kit = q( p 1t ,..., p Kt , Y it ,ε it ; Z it ), ∀k = 1,...,K .
The rest of the paper is organized as follows: A presentation of our underlying theoretical model and empirical specification is given in Section 2, followed by our econometric estimation procedure in Section 3. We describe the data used to estimate in empirical model in Section 4
and present the estimation results Section 5. Section 6 concludes with a discussion of the results in light of past findings in this area and current policy issues.
Theoretical and Empirical Approach
Following the standard neoclassical approach to consumer demand, suppose that an individual i = 1,..., N in time period t = 1,...,T has preferences over their health, H t , and a composite commodity of all other goods, C t , defined by the following utility function:
(1)
Further assume that health is a stock variable defined by an initial level of health carried over from the previous period, investments in health made through the consumption of medical services, m kit , k = 1,..., K, and random shocks, ε it , such that
To determine the optimal investment in health and consumption of other goods, the individual maximizes (1) and (2) subject to a budget constraint,
where Y it represents total disposable income, and the price of the composite commodity has been normalized to one. The resulting demand equations for medical services, which can be easily modified to include exogenous socio-demographic determinants, Z t , take the form:
Although the above derivation is straightforward, complete specification of the demand equations is complicated by the presence of medical insurance and the nonlinear pricing schedules commonly applied to medical care. In particular, deductibles, coverage ceilings, and non-constant cost sharing between consumers and insurers make it difficult to determine the effective price of medical services. Newhouse, Phelps, and Marquis (1980) The empirical model for a demand system composed of K types of medical services can thus be specified to take the form
e pd kit where is a binary variable = 1 if the individual i's expected end-of-year price for medical service k is equal to zero and = 0 otherwise, and c i is a stochastic time-invariant individual 2 Even after allowing for risk aversion, the expected end-of-year price remains close to the shadow price of medical services. Note that the use of expected end-of-year prices allows one to incorporate supply constraints imposed by insurers into the model that limit the number of covered visits. This is done by estimating each consumer's expectation, or probability, that the coverage limit is exceeded and subsequent expenses not reimbursed.
specific effect measuring unobserved heterogeneity. 3 We interpret c i as unobserved mental and physical health status and propensity to consume treatment; in cross-sectional formulations of the model, c i is typically either assumed to be zero or uncorrelated with all other regressors. If the vector of disturbances ε it = (ε 1it ,...,ε Kit )′ is assumed to be jointly distributed N (0,σ ε 2 ) , then the system of K equations defined by (6) is correlated through both c i and ε it .
The logarithmic specification of price and income variables in (6) is similar to other commonly used specifications in the empirical demand literature, and is necessary to account for the skewed distributions of these variables. The distribution of medical care prices (expected out-of-pockets costs), however, is not only skewed to the right, but contains a large mass at zero due to the fact that many individuals are enrolled in health insurance plans where the majority of their out-of-pocket costs are zero after paying an annual premium. This may occur, for example, if the some types of medical services require no co-payment (e.g. preventive services), or an individual's expenditures within a plan-year are large enough to exceed a stop-loss provision, whereby all remaining services in any service category do not require a co-payment. We account for this feature of the price distribution through the use of the binary variables to indicate zero expected end-of-year prices and logged positive prices. In contrast to out-of-pocket costs, the health insurance premium is an anticipated expense not linked to any particular health care transaction, and therefore, has been subtracted from total disposable income (that is, 
where υ i is assumed to be independent of the exogenous regressors and ε it and is distributed N (0,σ υ 2 ) . 4 This specification was originally derived by Chamberlain (1980) and has been applied to demand systems by Meyerhoefer, Ranney and Sahn (2005) . Defining x it as a row vector containing all the model regressors for time period t (plus a constant for the intercept), (7) is substituted into (6) to derive the demand system with reduced form parameter vector π kt = (π′ kt1 ,..., π′ ktT ) and normally distributed disturbance u kit = ε kit + υ i :
Econometric estimation of the CRE model generally proceeds by first obtaining consistent estimates of the reduced form parameters in (8) followed by identification of the structural parameters of interest in (6).
Econometric Estimation
In comparison to most commodities and many other services, medical services are difficult to measure in homogeneous units. Not only is there wide variation in the quality of medical care, but some medical procedures are very resource intensive while others are easily administered. In order to limit heterogeneity in the type of services provided we focus on ambulatory care and exclude inpatient treatment. We also follow the approach of previous
If c i is assumed to be orthogonal to a subset of the demographic variables, then restriction should be imposed for this subset in (7).
studies (such as Horgan 1986; Zuvekas, 1999; Winkelmann, 2004) in measuring ambulatory medical service use through the number of visits to physicians or other medical personnel, and analogously, measure pharmaceutical consumption through the number of prescription drug fills and/or re-fills during a one year time period. Finally, we disaggregate outpatient treatment into mental health ambulatory care, physical health ambulatory care, mental health related prescription pharmaceuticals, and physical health related prescription pharmaceuticals.
Irrespective of whether the medical service provided is an ambulatory visit or prescribed medicine, the distribution of consumption is highly skewed, particularly for the treatment of less common chronic conditions, such as mental illness. This is because most individuals have very few visits and prescription fills in a given year, while some individuals have a large number. In addition, for services such as mental health care there are a high proportion of non-consumers of both ambulatory treatment and prescription drugs. We use a zero-inflated ordered probit (ZIOP) specification, developed by Harris and Zhao (2004) to model the demand for medical services in the presence of this skewed distribution for ambulatory visits and prescription fills. Doing so allows us to capture the large probability mass at zero as well as define discrete categories containing a range of visit/fill enumerations at the upper end of the consumption distribution rather than just a single number of total visits.
Other popular empirical specifications used to model this type of data generating process include count data models, such as the zero-inflated Poisson or negative binomial specifications.
Our choice of the ZIOP model stems primarily from the desire to incorporate correlated random effects into the model, which is more tractably done using an index function with normally distributed disturbances. In addition, we find the ordered probit framework conceptually attractive when modeling numbered outcomes within specified ranges as well as individually.
Both Cameron and Trivedi (1998) and Wooldridge (2002) propose the ordered probit as an alternative to count data models, with the former demonstrating that it fits selected data on the number of doctor visits at least as well as a negative binomial model.
Underlying the ZIOP specification is a latent model of the demand for medical care in which observed consumption levels, m k , are generated as
The variable r k is a binary indicator dividing individuals into "consumers" and non-consumers" and is itself defined by the latent process where j = 1,..., J indexes ambulatory visit or prescription fill number. Although there is no requirement that the data vector x be the same in (10) and (11), in our application there are no variables which effect the likelihood of consuming medical services, but not effect the level of their consumption (or vice versa). Under the above formulation a zero outcome is observed if either the individual is a non-consumer of the service in question ( r k = 0 ) or is a consumer, but an infrequent one ( ). Likewise, to observe a non-zero outcome the individual must
be a consumer, or market participant, and have a positive consumption level during the respective time period.
Under the assumption that u k A and u k B are both independently and identically distributed N (0,1) , the full unconditional probabilities of the ZIOP model take the form:
As Harris and Zhao point out, this specification is analogous to other Zero Inflated models (see, for example, Mullahy (1986 Mullahy ( , 1997 , Greene (1994) , and Pohlmeier and Ulrich (1995) ) and is directly comparable to the double hurdle models following from Craig (1971) .
Estimation of the medical services demand system using the ZIOP specification is a multi-step process in which the reduced form parameter estimates in equation (8) Meyerhoefer, Sahn, and Ranney demonstrate how identification of the structural parameters in equation (6) is achieved through the use of a minimum distance estimator of the form:
. (13) Here ψ denotes the vector of structural parameters, Ω is the estimated covariance matrix of the reduced form parameter estimates, and H is a design matrix mapping the structural parameters to the reduced form estimates. In this case, the estimated covariance matrix Ω is adjusted using the formulae derived by Wooldridge (2002, pp.354-56) to account for the first-stage estimation of the predicted probabilities used to construct the expected price variables. The minimum distance framework provides a means of testing the validity of restrictions on the model as well as other nested or non-nested specifications through the use of the chi-squared distributed test statistic ND(ψ ) .
Data
The data source for our empirical application is the 1996 - Appendix Table A1 lists descriptive statistics for all of the variables used in the medical services demand model. Socio-demographic controls include race, gender, age and its square, years of completed education, self-reported physical and mental health status, the Columbia impairment scale for children, and a deterministic time trend. The insurance variables are dichotomous and indicate whether the respondent was fully or partially enrolled in a private insurance program (including TRICARE), or one of two categories of public insurance:
Medicare or Medicaid / other state program. 6 We also include an indicator for whether the private or public insurance program was administered through an HMO or managed care organization. Employment related variables include indicators for whether the respondent received paid sick leave and paid vacation at their current job. All of the price variables and logged family income have been adjusted for inflation and are reported in 2003 USD. In addition, the family's annual out-of-pocket premium has been subtracted from income, which is deflated by the square root of household size in order to adjust for household economies of scale.
We do not age-restrict the sample, and therefore, use the parent's labor market and education information for respondents under the age of 18. Variables marked by an * in Table A4 are those that we have specified as correlated with the random effect in our empirical specification. Table A2 contains detailed distributions on the components of expected end-of-year prices for the full sample. These include (pre-imputation) unit prices at each point on the eight segment price schedule as well as the predicted probabilities of facing an end-of-year price on each segment.
The dependent variables in the correlated random effects ZIOP model are the number of mental health and physical health ambulatory visits and prescription drug fills. 7 Because some respondents report very large numbers of visits and fills, while the majority report zero or a handful of visits, we define the dependent variable categories of the model as listed in Table 1 .
The categorization of larger numbers of visits is designed to correspond to changes in the price schedules of typical insurance plans. For example, many privately administered plans increase cost sharing after 5 visits and impose a coverage limit of 20 mental health visits per year. The expected end-of-year prices also correspond to these segments of the pricing schedule, so that out-of-pocket costs (prior to probability weighting) for categories 7, 8, and 9 are averages of the per visit or per prescription costs faced by consumers over the respective ranges.
Although every respondent has a non-zero probability of facing the end-of-year price associated with each of the categories in Table 1 , out-of-pocket costs are only observed for events that actually transpired. Therefore, we impute the out-of-pocket costs respondents would have faced had they consumed ambulatory medical services or prescription drugs at each level of the pricing schedule. This is done separately for the privately insured, uninsured, Medicare recipients, and Medicaid recipients on each segment of the pricing schedule in Table 1 using a two-stage regression-based imputation procedure.
In the first stage of the imputation procedure, a probit model is estimated on the sample of consumers with observed out-of-pocket costs to determine the probability of facing positive out-of-pocket costs for the respective visit or prescription fill. The estimates are subsequently used to generate an unbiased estimated of the latent outcome variable underlying the probit r k model (analogous to in (10)) for the sample of non-consumers. This is done by multiplying the estimated coefficients by each non-consumer's data vector and adding the value of a random draw from the distribution N (0,1) . Non-consumers with a predicted latent outcome less than or equal to zero are imputed an out-of-pocket cost of zero for the respective visit, while those with a positive latent outcome are run through a second imputation regression. This regression, also estimated on the sample of consumers, is an OLS model of segment-specific logged out-ofpocket cost on a variety of labor market and socio-demographic variables. 8 In addition, price variables from up to five previous segments of the pricing schedule are included to ensure imputed prices lie along a consistent trajectory. The imputation procedure preserves the distributional characteristics of observed out-of-pocket prices for each category of insurance coverage.
Estimation Results
Our principal purpose in estimating the demand models is to provide new estimates of the responsiveness of health care consumption to changes in health care prices so that they may be used in policy analysis. Therefore, we present own and cross-price effects of out-of-pocket prices for the four types of health care included in our empirical demand system: mental health 8 The probit and OLS imputation regressions include controls for age, race, sex, education level, marital status, family income, urbanization, census region, self-reported physical and mental health status, generosity of employer benefits, unionization, industry and occupation classification, employer size, HMO or managed care enrollee, and dummy variables for year of interview. Since the imputations are insurance-specific, no controls for insurance status are necessary.
visits, mental health drugs, physical health visits, and physical health drugs. For ease of interpretation, we compute two different price elasticity measures. First, arc elasticities between $0 and $5 dollars, $5 and $25, $25 and $75, and $75 and $100, are estimated by simulating the percentage change in the number of visits or prescription fills when out-of-pocket costs are constant over the range of expected demand and change (in percentage terms) by the specified dollar amounts. Second, we compute the average point elasticity, by taking derivatives of the expected quantity demanded with respect to the log of expected end-of-year price and dividing by expected demand. Both elasticity concepts are computed for each individual in the sample and averaged using sample weights to provide unbiased population estimates. Full regression results are reported in Table A3 for the cross-sectional model and in Table A4 for our preferred correlated random effects specification. All standard errors are adjusted for the complex design of the MEPS.
Own price effects
We present estimates of the own (out-of-pocket) price effects from our preferred correlated random effects (CRE) specification in Table 2 . The estimated average own-price elasticity for mental health visits is -.06, with arc elasticities changing little across price levels.
Ambulatory visits for physical health problems exhibit a slightly higher price elasticity of -.12.
The difference in physical and mental health visit price elasticities is statistically significant at the .001 level, but in economic terms they are similar in magnitude.
The demand for prescription drugs is substantially more price responsive. Mental health drugs are 10 times more price responsive than mental health visits, with an average elasticity of -.61. Furthermore, mental health drugs show an increasing arc elasticity of demand as the price level increases. The positive estimated arc elasticity in the range of $0-$5 is likely due to the small number of people facing $0 expected out-of-pocket cost for prescription drugs.
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Paralleling mental health, drugs for physical health problems have a higher price elasticity than physical health ambulatory visits, at -.29, but this is about half the estimated price elasticity for mental health drugs (difference is statistically significant at the .001 level). Like mental health drugs, however, physical health drugs elasticity of demand is increasing in out-of-pocket price.
We also compare own price effects from our CRE specification with estimates from the cross-sectional model in Table 2 . For mental health visits, the own price effects are identical.
However, the own price-effects for mental health drugs, physical health visits, and physical health drugs estimated are all smaller in our CRE specification compared to the cross-sectional estimates. Specification tests of whether the random effect term is orthogonal to the regressors strongly reject orthogonality, and the estimated λ parameters in the correlated random effects equation specification are also individually significant (see Table A4 ). Thus, we prefer the CRE specification.
Own price effect variations by health insurance coverage
While estimates of price effects across the entire population are of clear policy interest, public and private decision-makers also need to know price-responsiveness for particular populations defined by health insurance coverage. We therefore estimate our CRE specification separately for those covered by private insurance, Medicare, and Medicaid, as well as the uninsured, and present price elasticity estimates in Table 3 . Depending on the subgroup reported we have made small changes to the set of explanatory variables. For example, the dummy 9 When we estimate the model on subgroups in some cases there are almost no individuals that report a zero expected price for mental and physical health drugs. In these cases, the $0-$5 forecasts for drugs are outside of the range of the data.
variables indicating a zero expected end-of-year price for mental and physical health drugs have been dropped from all sub-categories except Medicaid.
In general, price responsiveness was greatest among the privately insured population.
Average own-price elasticities of demand for mental health and physical health visits were nearly identical at -.17 and -.16, respectively. However, mental health drugs were substantially more price elastic with an average elasticity of -.92, while the average elasticity for physical health drugs is -.26. Arc elasticities increased with price for both physical and mental health drugs.
Average price elasticities were lower among the Medicare population, with the exception of the large own-price elasticity of mental health drugs, -.89. However, physical health drugs did show some price responsiveness at higher out-of-pocket price levels. For example, the arc elasticity between $75 and $100 dollars was -.52. Estimated own-price elasticities for the Medicaid population were uniformly small across all four types of health care. This is not particularly surprising given the consistently low levels of cost sharing built into the Medicaid program.
For the uninsured, the own price effects for mental health and physical health visits were similar compared to the privately insured, although the former was not precisely estimated.
However, in contrast to the Medicare and privately insured population the demand for mental health drugs (-.28) was less price responsive than the demand for physical health drugs (-.51).
Cross-price elasticities: Substitutes or Complements?
A key question is whether pharmacotherapies serve as complements or substitutes for outpatient treatment. To answer this question, we compute cross-price elasticities across the four types of medical care and present these in Table 4 . For the entire population, the percentage change in the demand for physical health visits with respect to a one percent change in physical health drug price is -.07, while the analogous cross price elasticity of drug demand is -.03.
Therefore, our estimates suggest that physical health visits and drugs are gross complements, a result that is consistent within each different insured population. For example, the cross-price elasticities between physical health visits and drugs in the privately insured population are also -.07 and -.03. Mental health visits and drugs are also gross complements, although the symmetry is weaker. For the entire population, the percentage change in the demand for mental health visits with respect to a one percent change in mental health drug price is -.17, while the analogous cross price elasticity of drug demand is -.01. The general symmetry with respect to signs is a strong indication of the consistency in our demand estimates.
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Did price elasticities change between 1996 and 2003?
The MEPS data we use span an 8 year time period between 1996 and 2003, so it is natural to ask whether price elasticities changed over this period. Our base model includes a deterministic time trend as a regressor, but this cannot fully capture changes in elasticities because it is not interacted with the price variables. Instead, we split our sample into an early period with panels 1-4 (1996-2000) and a later period representing panels 5-7 (2000-2003) and re-estimate the CRE model for each. The results are presented in Table 5 . In general, the signs and magnitudes of both the own-price and cross price effects are quite similar in the early and more recent time periods, which increases confidence in the robustness of our approach. For example, the own price effects for physical health visits (-.11 for panels 1-4 vs. -.12 for panels 5-10 The symmetry restriction from economic theory implies that the cross price derivatives of the Hicksian demand functions are equivalent. Using the Slutsky equation one can derive an analogous condition for the Marshallian demands. We do not statistically restrict the cross price derivatives in our system of (Marshallian) demands to be symmetric, as many researchers do. However, our finding that symmetry generally holds with respect to sign suggests the model conforms to theory even without such a restriction. 
Robustness
While we find that the price elasticity of demand for physical health visits to be similar in magnitude to estimates from the RAND Health Insurance Experiment, our results also imply that the demand for outpatient mental health visits has become substantially less price elastic since the 1970s/early 1980s when the RAND study was conducted. Because of the potential policy importance of this finding, we want to be sure of its robustness. Obviously, the cost of a new randomized experiment is prohibitive. We also could not properly identify an instrumental variables model, a long-standing problem in health economics research. However, as we noted earlier, observational studies using data from the same time period as the RAND HIE also found substantial price responsiveness. We take advantage of the fact that one of these key studies by
Horgan (1986) used data from an earlier predecessor of the MEPS data we use, the 1977 National Medical Care Expenditure Survey (NMCES).
Horgan estimated a standard two-part cross-sectional model of the demand for outpatient specialty mental health visits, predicting the probability of any use with a logit regression and modeling the log of the number of specialty mental health visits using an OLS regression. We are unable to replicate the first (logit) part of the model because we lack an equivalent price variable to the one Horgan used. However, we can estimate the second part of Horgan's cross- Thus, our re-estimation of Horgan's model with more current data yields similar results to our preferred specification. Namely, the demand for outpatient mental health visits appears to have become substantially less elastic over time. We still note that both our measure of expected price, which is theoretically more consistent than using observed prices, and our CRE specification to correct for potential endogeneity and time-invariant measurement error processes, are improvements over Horgan's model.
We performed a further robustness check on our results by investigating whether the use of expected end-of-year prices produces consistent elasticity estimates throughout the year.
Keeler, Newhouse, and Phelps (1997) have shown that the true shadow price of healthcare varies throughout the year as consumers update their information about how close they are to a discontinuity in their price schedule. Ellis (1986) demonstrates that the expected end-of-year price tracks the true shadow price of healthcare quite closely under fairly realistic assumptions, and shows empirically that estimates of the price responsiveness of demand are similar using expenditures from the first 30, 60, and 90 days of year. In a similar manner to Ellis, we reestimated our demand system using utilization data from round 1 of the MEPS, corresponding roughly to the first half of the year, and found that our own-price elasticities of demand varied by only 7 percent, on average. Therefore, the expected end-of-year price provides consistent measure of the consumers' perceived health care price. population is -.06, lower even than our estimate of -.12 for the own-price elasticity for physical health visits. For different insured subpopulations, there were no statistically significant differences in elasticities between physical and mental health visits.
Discussion and Conclusions
One of the reasons why our elasticity estimates are lower than those found by the RAND investigators may be due to structural and institutional changes to health care markets over the past twenty to thirty years, such as the diffusion of managed care. Although we control for different types of insurance and enrollment in an HMO or managed care plan, all types of health care services are more highly managed than they once were. This is particularly true of mental health services, where the distinction between managed and traditional plans is blurred by the common use of carve-out arrangements to control costs. Therefore, our elasticity estimates should be interpreted as conditional on the current institutional environment, and are more appropriate for forecasting price changes within this environment than wholesale changes to the environment itself.
If it is indeed true that the price responsiveness of mental health ambulatory treatment is less than or equal to physical health treatment, then the justification for higher cost-sharing for mental health based purely on efficiency grounds would no longer hold. This has significant implications for private health insurance plans and Medicare (and to a lesser extent Medicaid), where mental health treatment continues to be covered much less generously on average than other medical services. It also suggests that increasing the generosity of outpatient mental health coverage would not lead to large cost increases, which is consistent with studies of the impact of state legislative mandates for mental health parity, that is, equal coverage for mental health and physical health treatment (Zuvekas et al. 2002; Sturm, 1997; Goldman et al, 2006) .
Our results also point to the importance of prescription drug treatment in the overall demand for mental health care. Estimates of the own-price elasticity of demand for mental health drugs are substantially higher than for outpatient mental health visits (with the exception of the Medicaid population). We also note the high, negative cross-price elasticities between mental health drugs and visits. Together, this suggests that many mental health visits are for medication management and that individuals' overall demand for mental health treatment is now more strongly tied to prescription drug than ambulatory costs than it was during the RAND HIE.
In other words, the decision to begin and continue mental health treatment is now more heavily influenced by the expected costs of the appropriate course of mental health drugs than the associated ambulatory costs.
Turning to physical health treatment, our estimates of the own-price elasticity of demand for visits are similar in magnitude to those reported from the RAND HIE. That is to say, price elasticities appear to remain small, but they are also not zero as the RAND HIE investigators point out (Manning et al 1987) . Because spending on ambulatory visits exceeds $300 billion annually (MEPS Compendia of Tables, 2003) , the scope for significant aggregate welfare losses is substantial.
Our findings suggest, however, that concerns about efficiency losses from moral hazard resulting from insurance coverage are better focused on prescription drug coverage rather than coverage for ambulatory care. We found the elasticity of expected out-of-pocket price to be substantially greater for prescription drugs: -.61 for mental health drugs and -.29 for physical health drugs. In contrast, the RAND HIE found little difference in the price elasticity of demand for prescription drugs and other services (Newhouse et al., 1993 In sum, price responsiveness remains heterogeneous in type of health care treatment,
although it also appears that price responsiveness for particular treatments changed in the last 25-30 years. We find that there are no longer differences in price effects between ambulatory mental health and physical health visits, but substantially higher price responsiveness in prescription drugs, especially mental health drugs. The theory of optimal second-best insurance coverage suggests that health insurance plans, including those combined with Health Savings Accounts, may need to adjust coverage to reflect changes in the underlying demand for medical services.
Limitations and Future Research
It is quite possible that radical changes in the treatment technology for mental health, such as the move away from outpatient psychotherapy towards pharmacotherapy, explain the observed decrease in the own-price responsiveness of mental health ambulatory treatment.
However, we must also consider the impact of managed behavioral healthcare in constraining supply. The price elasticity estimates of 25-30 years ago come largely from a fee-for-service world unconstrained by managed care organizations that may restrict access to or the supply of mental health services. For example, a managed behavioral healthcare organization may authorize and pay for 5 outpatient treatment visits, but no more. In this case, the consumer faces the full marginal cost of any additional treatment visits. We model the resulting nonlinearity in consumers' price schedules by computing expected end-of-year prices. However, the validity of this measure rests in our ability to accurately model the consumer's expectations. If the covariates in our model do not accurately characterize consumer's information set, then our predictions will be biased.
Price schedules for prescription drugs have also become increasingly nonlinear.
Prescription drug plans today typically require the lowest consumer cost-sharing for generic medications no longer covered by patents, higher cost-sharing for favored drugs (often as a result of negotiations with pharmaceutical companies), and still higher cost-sharing for non-favored drugs. Further disaggregating prescription drugs to explicitly correspond to these types of tiered pricing schedules that differentiate between generic versus non-generic medications (as well as among non-generics) represents a promising extension of our empirical approach.
The MEPS data make it difficult to fully sort out medication management visits from traditional psychotherapy and from newer forms of behavioral therapy. Data for the 1996 through 2001 period also do not allow us to distinguish whether mental health visits were to primary care physicians or psychiatrists. Beginning in 2002, the MEPS added questions about physician specialty, but we do not yet have enough years of data to apply our panel data estimation techniques. It is quite possible that price elasticities differ for these different forms of mental health treatment, which is something we intend to explore in future work.
Another limitation of our modeling approach is that our method for accounting for endogeneity and meaurment error is not fully general. We assume that the endogeneity of price, health insurance status, and self-reported measures of physical and mental health is generated by correlation with a component of the residual that is time invariant. This is logical given the supposition that unobserved physical and mental health status and propensity of consume treatment are the primary confounders of these variables. However, it is also possible that there exists a correlation between the regressors with time varying error components that we cannot capture. The same is true of measurement error considerations. If the process generating differences between consumers' true expected end-of-year price and our construct is not time invariant, then our parameter estimates will be attenuated. 11 Finally, we identify the correlation between the random effect and included regressors using just two time periods, so that the effect of regressors three periods removed is present in the model's residual. If the included regressors exhibit strong serial correlation then some endogeneity bias may persist despite our attempt to "integrate out" the random effect. However, the lack of suitable instruments for price and insurance makes our approach to correcting for endogeneity and measurement error attractive.
The prospects for another large-scale randomized experiment remain dim given current federal budget forecasts-the RAND HIE cost $136 million to conduct in 1984 dollars (Manning et al., 1987) . Thus, more current estimates of price elasticities must come from observational studies. We believe our correlated random effects approach, correcting for the clear endogeneity of prices and health insurance and applied to multiple years of data from the nationally representative MEPS, offers a second-best solution. 
